Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 3Carcinoma, Pancreatic Ductal 2Stomach Neoplasms 1Recurrence 1Pancreatic Adenocarcinoma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 14Cisplatin 13Capecitabine 11Oxaliplatin 9Fluorouracil 9130-nm albumin-bound paclitaxel 9Paclitaxel 8pembrolizumab 7Ramucirumab 6Leucovorin 6Carboplatin 6Bevacizumab 6Albumin-Bound Paclitaxel 6Pemetrexed 4Nivolumab 4Irinotecan 4Everolimus 4Erlotinib Hydrochloride 4Docetaxel 4Cyclophosphamide 4trastuzumab deruxtecan 3Radiotherapy 3Afatinib 3zolbetuximab 2pralsetinib 2cabozantinib 2Trastuzumab 2Ipilimumab 2vosaroxin 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenocarcinoma × PEGPH20 × Clear all
NCT02487277 2020-01-02

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

University of California, San Francisco

Phase 2 Terminated
3 enrolled 8 charts
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡